Advances in the Study of Liver Cancer Stem Cells
DOI:
https://doi.org/10.54097/nz8k3418Keywords:
LCSCs; hepatocarcinogenesis and progression; targeted drugs; immunotherapy; vaccines.Abstract
Liver cancer is one of the deadliest cancers in the world, and liver cancer stem cells (LCSCs) is a key factor in liver cancer pathogenesis, treatment resistance and disease recurrence. Despite significant advances in the understanding of LCSCs over the past few years, their role in liver cancer pathology remains a challenge. This review addresses the characterization of LCSCs in hepatocellular carcinoma, methods of identification, therapeutic strategies, and how they affect disease progression and patient prognosis. This paper pays special attention to recent studies on molecular markers, signaling pathways, and gene expression characterization of LCSCs. The paper also evaluates a variety of potential therapeutic approaches, including targeted drug therapies against specific signaling pathways, cell surface markers, etc., immunotherapeutic strategies such as CAR-T cell therapy, and tumor vaccines. Although most of these therapeutic strategies are still in the research phase, they offer new hope for the treatment of liver cancer. Finally, this paper discusses the challenges faced in translating these laboratory studies into clinical treatments, as well as potential directions for future research.
Downloads
References
Zakrzewski, W., Dobrzyński, M., Szymonowicz, M., & Rybak, Z. Stem cells: past, present, and future. Stem cell research & therapy, 2019, 10(1), 1-22.
Prager, B. C., Xie, Q., Bao, S., & Rich, J. N. Cancer stem cells: the architects of the tumor ecosystem. Cell stem cell, 2019, 24(1), 41-53.
Matthews, H. K., Bertoli, C., & de Bruin, R. A. Cell cycle control in cancer. Nature Reviews Molecular Cell Biology, 2022, 23(1), 74-88.
Wang, R., Sun, Q., Wang, et al. Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells. Oncotarget, 2016, 7(5), 5754.
Pan, L., Feng, F., Wu, J., et al. Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. Pharmacological research, 2022, 181, 106270.
Liu, Y. C., Yeh, C. T., & Lin, K. H. Cancer stem cell functions in hepatocellular carcinoma and comprehensive therapeutic strategies. Cells, 2020, 9(6), 1331.
Emami Nejad, A., Najafgholian, S., Rostami, A., Sistani, A., Shojaeifar, S., Esparvarinha, M., ... & Manian, M. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell International, 2021, 21(1), 1-26.
Lee, T. K. W., Guan, X. Y., & Ma, S. Cancer stem cells in hepatocellular carcinoma—From origin to clinical implications. Nature Reviews Gastroenterology & Hepatology, 2022, 19(1), 26-44.
Xu, Y., Hu, Y. D., Zhou, J., & Zhang, M. H. Establishing a lung cancer stem cell culture using autologous intratumoral fibroblasts as feeder cells. Cell Biology International, 2011, 35(5), 509-517.
Sun, J. H., Luo, Q., Liu, L. L., & Song, G. B. Liver cancer stem cell markers: Progression and therapeutic implications. World journal of gastroenterology, 2016, 22(13), 3547.
Zhu, K., Li, J., Li, J., Sun, J., et al. Ring1 promotes the transformation of hepatic progenitor cells into cancer stem cells through the Wnt/β‐catenin signaling pathway. Journal of Cellular Biochemistry, 2020, 121(8-9), 3941-3951.
Kahraman, D. C., Kahraman, T., & Cetin-Atalay, R. Targeting PI3K/Akt/mTOR pathway identifies differential expression and functional role of IL8 in liver cancer stem cell enrichment. Molecular cancer therapeutics, 2019, 18(11), 2146-2157.
Kadkhoda, J., Akrami-Hasan-Kohal, M., Tohidkia, M. R., Khaledi, S., Davaran, S., & Aghanejad, A. Advances in antibody nanoconjugates for diagnosis and therapy: A review of recent studies and trends. International journal of biological macromolecules, 2021, 185, 664-678.
Chao, J., Zhao, S., & Sun, H. Dedifferentiation of hepatocellular carcinoma: molecular mechanisms and therapeutic implications. American Journal of Translational Research, 2020, 12(5), 2099.
Duan, R., Du, W., & Guo, W. EZH2: a novel target for cancer treatment. Journal of hematology & oncology, 2020, 13(1), 1-12.
Wu, Y., Liu, H., & Ding, H. GPC-3 in hepatocellular carcinoma: current perspectives. Jusnal of hepatocellular carcinoma, 2016, 63-67.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







